Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Capital Expenditures (2021 - 2025)

Krystal Biotech's Capital Expenditures history spans 5 years, with the latest figure at -$6.7 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 942.07% year-over-year to -$6.7 million; the TTM value through Dec 2025 reached $3.1 million, down 27.63%, while the annual FY2025 figure was $3.1 million, 27.63% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$6.7 million at Krystal Biotech, down from $8.5 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $17.2 million in Q1 2022 and bottomed at -$32.8 million in Q4 2022.
  • The 5-year median for Capital Expenditures is $1.8 million (2021), against an average of $2.5 million.
  • The largest annual shift saw Capital Expenditures skyrocketed 896.19% in 2024 before it crashed 942.07% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at -$7.8 million in 2021, then plummeted by 318.28% to -$32.8 million in 2022, then surged by 102.12% to $696000.0 in 2023, then increased by 15.09% to $801000.0 in 2024, then plummeted by 942.07% to -$6.7 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Capital Expenditures are -$6.7 million (Q4 2025), $8.5 million (Q3 2025), and -$4.9 million (Q2 2025).